Fruquintinib Plus FOLFIRI/FOLFOX as Second‐Line Therapy in Patients With RAS‐Mutant Metastatic Colorectal Cancer: A Multicenter, Open‐Label, Single‐Arm Phase II Study
- DOI
- 10.1002/mco2.71137
- Published
- 2026-11
- Container
- MedComm
- Publisher
- Wiley
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1002/mco2.71137,
title = {Fruquintinib Plus FOLFIRI/FOLFOX as Second‐Line Therapy in Patients With RAS‐Mutant Metastatic Colorectal Cancer: A Multicenter, Open‐Label, Single‐Arm Phase II Study},
author = {Yun Xu and Cong Li and Yiwei Zeng and Yuchen Wu and Yuedi Dai and Xiaopin Ji and Zhe Cui and Xiaodong Zhu and Ming Tang and Ye Xu},
year = {2026},
journal = {MedComm},
doi = {10.1002/mco2.71137},
url = {https://doi.org/10.1002/mco2.71137}
}RIS
TY - JOUR TI - Fruquintinib Plus FOLFIRI/FOLFOX as Second‐Line Therapy in Patients With RAS‐Mutant Metastatic Colorectal Cancer: A Multicenter, Open‐Label, Single‐Arm Phase II Study AU - Yun Xu AU - Cong Li AU - Yiwei Zeng AU - Yuchen Wu AU - Yuedi Dai AU - Xiaopin Ji AU - Zhe Cui AU - Xiaodong Zhu AU - Ming Tang AU - Ye Xu PY - 2026 JO - MedComm DO - 10.1002/mco2.71137 UR - https://doi.org/10.1002/mco2.71137 ER -
APA
Xu, Y., Li, C., Zeng, Y., Wu, Y., Dai, Y., Ji, X., Cui, Z., Zhu, X., Tang, M., & Xu, Y. (2026). Fruquintinib Plus FOLFIRI/FOLFOX as Second‐Line Therapy in Patients With RAS‐Mutant Metastatic Colorectal Cancer: A Multicenter, Open‐Label, Single‐Arm Phase II Study. MedComm. https://doi.org/10.1002/mco2.71137
Source records
- crossref · retrieved 2026-11-10T19:01:10.454Z